Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Co. Ltd.

www.eisai.com

Latest From Eisai Co. Ltd.

Court Restrains Dr Reddy’s In Indian Belviq Case

An Indian court has granted an interim injunction against Dr Reddy’s in a case concerning the alleged infringement of Eisai’s patent on Belviq. Dr Reddy’s, however, claims that Eisai is a “patent squatter” and expects to appeal against the order.

Commercial Strategy

Polyphor's Stock Slides As Murepavadin Trials Are Halted

The Switzerland-headquartered group has suffered a setback as a couple of Phase III trials of its lead antibiotic were stopped temporarily after an unexpectedly high number of patients reported kidney injury.

Infectious Diseases Clinical Trials

Eisai's New Venture Fund Looks To ‘Excavate’ Innovation

Japanese pharma firm’s new venture capital fund aims to support and gain access to external innovation both at home and in the US, while a new alliance with a Japanese tech services firm will pursue opportunities in digital health and dementia.

Japan Financing

Calm Before The Storm: Pharma Opens 2019 With A Bang In China

Products old, new and reimbursed were the driving force for foreign drug firms including AstraZeneca, Merck and Pfizer and Sanofi to smash growth in China in the first quarter.

China Business Strategies
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register